Get the Stockscreener App
21.62
1.95%
-0.43
Catalyst Pharmaceuticals Inc stock is traded at $21.62, with a volume of 901.05K.
It is down -1.95% in the last 24 hours and down -5.67% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
See More
Previous Close:
$22.05
Open:
$22.26
24h Volume:
901.05K
Relative Volume:
0.90
Market Cap:
$2.58B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
18.32
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
-7.09%
1M Performance:
-5.67%
6M Performance:
+5.62%
1Y Performance:
+57.70%
1-Day Range:
$21.35
$22.27
1-Week Range:
$21.35
$23.59
52-Week Range:
$13.49
$24.64
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.62 | 2.58B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely - Simply Wall St
Allspring Global Investments Holdings LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stake Raised by Allspring Global Investments Holdings LLC - Defense World
Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Has $8.71 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals stock hits all-time high of $24.44 - MSN
Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374% - Yahoo Finance
Yousif Capital Management LLC Has $903,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Advisors Preferred LLC Takes $1.08 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - GlobeNewswire
Catalyst Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - Nasdaq
Earnings Alert: Catalyst Pharmaceuticals Sets Key Q4 Financial Results DateStrategic Updates Expected - StockTitan
abrdn plc Acquires Shares of 484,666 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Spire Wealth Management - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to "Strong-Buy" at Baird R W - MarketBeat
Short Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Rises By 12.5% - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated by Analysts at Robert W. Baird - MarketBeat
Catalyst Remains a Big Money Favorite - FX Empire
Robert W. Baird Initiates Coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Baird Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Outperform Recommendation - MSN
Baird starts Catalyst Pharma with Outperform, $28 target - MSN
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Baird Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $28 Price Target - Marketscreener.com
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock - Benzinga
SG Americas Securities LLC Buys 24,102 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Up 5.4%Time to Buy? - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 12-Month HighWhat's Next? - MarketBeat
CPRX: 3 Niche Healthcare Stocks Tackling Rare Diseases - StockNews.com
Nilsine Partners LLC Invests $700,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Moody Aldrich Partners LLC Trims Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
EMC Capital Management Has $308,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by SG Americas Securities LLC - Defense World
Catalyst Pharmaceuticals stock hits all-time high of $24.44 By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):